Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Animal models of neurodevelopmental disorders treated with TAK-418

ABSTRACT: Animal models of neurodevelopmental disorders treated with TAK-418

PROVIDER: PRJNA695298 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13565200.fastq.gz	Fastqsanger.gz
	SRR13565600_1.fastq.gz	Fastqsanger.gz
	SRR13565600_2.fastq.gz	Fastqsanger.gz
	SRR13565201.fastq.gz	Fastqsanger.gz
	SRR13565601_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 146

Similar Datasets

DNA methylation profile in animal models of neurodevelopmental disorders treated with TAK-418

Project description:We report the DNA methylation profiles in the brain cortex of animal models of neurodevelopmental disorders (rat with prenatal exposure to valproate and mouse with prenatal exposure to poly I:C) treated with TAK-418.

2021-01-29 | GSE165675 | GEO

RNA expression profile in animal models of neurodevelopmental disorders treated with TAK-418

Project description:We report the RNA expression profiles in the brain cortex of animal models of neurodevelopmental disorders (rat with prenatal exposure to valproate and mouse with prenatal exposure to poly I:C) treated with TAK-418.

2021-01-29 | GSE165660 | GEO

Histone modification profile in animal models of neurodevelopmental disorders treated with TAK-418

Project description:We report the histone modification profiles in the brain cortex of animal models of neurodevelopmental disorders (rat with prenatal exposure to valproate and mouse with prenatal exposure to poly I:C) treated with TAK-418.

2021-01-29 | GSE165655 | GEO

DNA methylation profile in animal models of neurodevelopmental disorders treated with TAK-418

Project description:DNA methylation profile in animal models of neurodevelopmental disorders treated with TAK-418

| PRJNA695299 | ENA

RNA expression profile in animal models of neurodevelopmental disorders treated with TAK-418

Project description:RNA expression profile in animal models of neurodevelopmental disorders treated with TAK-418

| PRJNA695277 | ENA

Histone modification profile in animal models of neurodevelopmental disorders treated with TAK-418

Project description:Histone modification profile in animal models of neurodevelopmental disorders treated with TAK-418

| PRJNA695268 | ENA

Animal models of neurodevelopmental disorders treated with TAK-418

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-01-29 | GSE165676 | GEO

TAK-418-418, a LSD1 inhibitor, can rescue the genome wide chromatin abnormality in hippocapmus tissue in KMT2D+/bGeo mice after 2 week treatment [RNA-seq]

Project description:Mutation in KMT2D, a histone-lysine N-methyl transferase, is responsible for majority of Kabuki syndrome in human. A mouse model of Kabuki syndrome with heterzygous mutation of KMT2D, KMT2D+/bGeo was created to understand the disease mechanism and for drug discovery. TAK-418-418, a lysine-specific histone demethylase (LSD1) inhibitor, was tested on these mice for therapeutic treatment of the disease. Differences between expression levels among different experimental conditions was evaluated by high throughput RNA sequencing (RNA-Seq).

2020-03-11 | GSE146728 | GEO

TAK-418-418, a LSD1 inhibitor, can rescue the genome wide chromatin abnormality in hippocapmus tissue in KMT2D+/bGeo mice after 2 week treatment [ChIP-seq]

Project description:KMT2D+/bGeoation in KMT2D, a histone-lysine N-methyl transferase, is responsible for majority of Kabuki syndrome in human. A mouse model of Kabuki syndrome with heterzygous KMT2D+/bGeoation of KMT2D, KMT2D+/bGeo was created to understand the disease mechanism and for drug discovery. TAK-418-418, a lysine-specific histone demethylase (LSD1) inhibitor, was tested on these mice for therapeutic treatment of the disease. Rescue of genome wide chromatin abnormality, which has been reported in KMT2D+/bGeo mice, was evaluated by high throughput next generation sequencing following chromatin immunoprecipitation of H3K4me1 and H3K4me3.

2020-03-11 | GSE146727 | GEO

Gene dosage imbalance in neurodevelopmental disorders

Project description:Gene dosage imbalance in neurodevelopmental disorders

| PRJNA287736 | ENA